{'fraction_non_alphanumeric': 0.02450229709035222, 'fraction_numerical': 0.0030627871362940277, 'mean_word_length': 4.787610619469026, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Point‐of‐care instruments need to offer high levels of accuracy

We appreciate the interest shown by Heffler et al in our paper on the HemoCue WBC DIFF instrument (1). Considering the return of eosinophils as markers in asthma monitoring (eosinophilia) or in sepsis (eosinopenia) it is important to remind ourselves how the levels of measured blood cells are influenced by the performance of an analytical instrument. We fully agree with Heffler et al (2) that the HemoCue WBC DIFF's results should be interpreted in the context of the clinical setting or medical condition of the patient. 
 
This article is protected by copyright. All rights reserved.